Simple risk algorithm to predict serious bleeding in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention - RISK-PCI bleeding score

Circulation Journal

Volumn 77, Issue 7, 2013, Pages 1719-1727

  Mrdovic, Igor ^a,b   Savic, Lidija ^b   Krljanac, Gordana ^a,b   Asanin, Milika ^a,b   Lasica, Ratko ^a,b   Djuricic, Nemanja ^b   Brdar, Natasa ^b   Marinkovic, Jelena ^a,c   Kocev, Nikola ^a,c   Perunicic, Jovan ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Institute for Medical Research   (Serbia)

Author keywords

Primary percutaneous coronary intervention; Risk score; Serious bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PANTOPRAZOLE; RANITIDINE; TIROFIBAN; VASOACTIVE AGENT;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENDER; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; RETROPERITONEAL HEMORRHAGE; RISK FACTOR; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBUS;

AGED; ALGORITHMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84879338359     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1177     Document Type: Article

References (40)

1. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ, for the CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2009; 157: 369-374.
2. Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, et al; for the GRACE Investigators. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 2007; 116: 2793-2801.
3. Bassand JP. Bleeding and transfusion in acute coronary syndromes: A shift in the paradigm. Heart 2008; 94: 661-666.
4. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930-935.
5. Rao SV, O'Grady K, Pieper KS, Newby LK, Van de Werf F, Mahaffey KW, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-1206.
6. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: A risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-1466.
7. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KAA, Shao M, et al; for the CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial. Circulation 2010; 121: 2575-2583.
8. Lindsey JB, Marso SP, Pencina M, Stolker JM, Kennedy KF, Rihal C, et al; on behalf of the EVENT Registry Investigators. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: Results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) registry. J Am Coll Cardiol Interv 2009; 2: 1074-1082.
9. Budaj A, Eikelboom JW, Mehta SR, Afza R, Chrolavicius S, Bassand JP, et al; on behalf of OASIS 5 Investigators. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009; 30: 655-661.
10. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28: 1936-1945.
11. Yip HK, Chung SY, Chai HT, Youssef AA, Bhasin A, Yang CH, et al. Safety and efficacy of transradial vs transfemoral arterial primary coronary angioplasty for acute myocardial infarction: Single-center experience. Circ J 2009; 73: 2050-2055.
12. Mrdovic I, Savic L, Krljanac G, Perunicic J, Asanin M, Lasica R, et al. Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention: The RISK-PCI score. Int J Cardiol 2013; 162: 220-227.
13. Mrdovic I, Savic L, Krljanac G, Asanin M, Perunicic J, Antonijevic N, et al. Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention: The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial. Int J Cardiol 2012 May 22, doi:10.1016/j.ijcard.2012.04.129 [Epub ahead of print].
14. Mehran R, Rao S, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-2747.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardised definitions. Circulation 2007; 115: 2344-2351.
16. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 809-816.
17. Jolicoeur EM, O'Neill WW, Hellkamp A, Hamm CW, Holmes Jr DR, Al-Khalidi HR, et al; for the APEX-AMI investigators. Transfusion and mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2009; 30: 2575-2583.
18. Moscucci M, Fox KAA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al; for the GRACE Investigators. Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-1823.
19. Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak RN, et al; RUGBE Investigators. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic haemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238-1246.
20. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based case-control study. BMJ 2006; 333: 726.
21. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al; on behalf of the National Cardiovascular Data Registry. Bleeding in patients undergoing percutaneous coronary intervention: The development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Intervent 2009; 2: 222-229.
22. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment elevation myocardial infarction the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. Circulation 2009; 119: 1873-1882.
23. Fuchs S, Kornowski R, Teplitsky I, Brosh D, Lev E, Vaknin-Assa H, et al. Major bleeding complicating contemporary primary percutaneous coronary interventions: Incidence, predictors, and prognostic implications. Cardiov Rev Med 2009; 10: 88-93.
24. Hermanides RS, Ottervanger JP, Dambrink JH, de Boer MJ, Hoorntje JC, Gosselink AT, et al. Incidence, predictors and prognostic importance of bleeding after primary PCI for ST-elevation myocardial infarction. EuroIntervention 2010; 6: 106-111.
25. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: Assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2010; 121: 43-51.
26. Mathis AS, Gugger JJ. Percutaneous coronary intervention-related bleeding risk factors in current practice. Ann Pharmacother 2005; 39: 1627-1632.
27. Brouse SD, Wiesehan VG. Evaluation of bleeding complications associated with glycoprotein IIb/IIIa Inhibitors. Ann Pharmacother 2004; 38: 1783-1788.
28. Eikelboom JW, Hirsh J. Combined antiplatelet and anticoagulant therapy: Clinical benefits and risks. J Thromb Haemost 2007; 5(Suppl 1): 255-263.
29. Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, et al; on behalf of the OASIS 5 and OASIS 6 Investigators. Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. Eur Heart J 2010; 31: 50-58.
30. Choi YH, Suh SH, Choi JS, Kim CS, Sim DS, Bae EH, et al; for the Korea Acute Myocardial Infarction Registry Investigators. Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction: Results from the Korea Acute Myocardial Infarction Registry. Circ J 2012; 76: 2405-2411.
31. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, van de Werf F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes, a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-198.
32. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction N Engl J Med 2001; 344: 1895-1903.
33. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, et al; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-1538.
34. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY trial. J Am Coll Cardiol 2007; 49: 1362-1368.
35. Kim JS, Park SM, Kim BK, Ko YG, Choi D, Hong MK, et al; ECLAT-STEMI Trial investigators. Efficacy of clotinab in acute myocardial infarction trial-ST elevation myocardial infarction (ECLATSTEMI). Circ J 2012; 76: 405-413.
36. Chung WY, Han MJ, Cho YS, Kim KI, Chang HJ, Youn TJ, et al. Effects of the early administration of heparin in patients with STelevation myocardial infarction treated by primary angioplasty. Circ J 2007; 71: 862-867.
37. Motovska Z, Widimsky P, Petr R, Andrasova A, Bilkova D. The time has come for new, more precise guidelines in the treatment of high-risk acute coronary syndromes with heparin. Circ J 2008; 72: 1674-1679.
38. Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, et al. Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial. Am J Cardiol 2009; 103: 917-922.
39. Hälg C, Brunner-La Rocca HP, Kaiser C, Jeger R, Osswald S, Pfisterer M, et al; for the BASKET investigators. Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulant therapy. EuroIntervention 2009; 5: 425-431.
40. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al; HORIZONS-AMI Trial Investigators. N Engl J Med 2008; 358: 2218-2230.